178 related articles for article (PubMed ID: 35064101)
21. Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway.
Li Y; Zhou H; Li F; Chan SW; Lin Z; Wei Z; Yang Z; Guo F; Lim CJ; Xing W; Shen Y; Hong W; Long J; Zhang M
Cell Res; 2015 Jul; 25(7):801-17. PubMed ID: 26045165
[TBL] [Abstract][Full Text] [Related]
22. The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer.
Li Z; Wang Y; Zhu Y; Yuan C; Wang D; Zhang W; Qi B; Qiu J; Song X; Ye J; Wu H; Jiang H; Liu L; Zhang Y; Song LN; Yang J; Cheng J
Mol Oncol; 2015 Jun; 9(6):1091-105. PubMed ID: 25704916
[TBL] [Abstract][Full Text] [Related]
23. Angiomotin is a novel component of cadherin-11/β-catenin/p120 complex and is critical for cadherin-11-mediated cell migration.
Ortiz A; Lee YC; Yu G; Liu HC; Lin SC; Bilen MA; Cho H; Yu-Lee LY; Lin SH
FASEB J; 2015 Mar; 29(3):1080-91. PubMed ID: 25466890
[TBL] [Abstract][Full Text] [Related]
24. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
25. Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression.
Hsu YL; Hung JY; Chou SH; Huang MS; Tsai MJ; Lin YS; Chiang SY; Ho YW; Wu CY; Kuo PL
Oncogene; 2015 Jul; 34(31):4056-68. PubMed ID: 25381822
[TBL] [Abstract][Full Text] [Related]
26. Hippo pathway and breast cancer stem cells.
Maugeri-Saccà M; De Maria R
Crit Rev Oncol Hematol; 2016 Mar; 99():115-22. PubMed ID: 26725175
[TBL] [Abstract][Full Text] [Related]
27. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein.
Zhao B; Li L; Lu Q; Wang LH; Liu CY; Lei Q; Guan KL
Genes Dev; 2011 Jan; 25(1):51-63. PubMed ID: 21205866
[TBL] [Abstract][Full Text] [Related]
28. AMOT is required for YAP function in high glucose induced liver malignancy.
Liu Y; Lu Z; Shi Y; Sun F
Biochem Biophys Res Commun; 2018 Jan; 495(1):1555-1561. PubMed ID: 29217192
[TBL] [Abstract][Full Text] [Related]
29. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.
Cordenonsi M; Zanconato F; Azzolin L; Forcato M; Rosato A; Frasson C; Inui M; Montagner M; Parenti AR; Poletti A; Daidone MG; Dupont S; Basso G; Bicciato S; Piccolo S
Cell; 2011 Nov; 147(4):759-72. PubMed ID: 22078877
[TBL] [Abstract][Full Text] [Related]
30. Modular mimicry and engagement of the Hippo pathway by Marburg virus VP40: Implications for filovirus biology and budding.
Han Z; Dash S; Sagum CA; Ruthel G; Jaladanki CK; Berry CT; Schwoerer MP; Harty NM; Freedman BD; Bedford MT; Fan H; Sidhu SS; Sudol M; Shtanko O; Harty RN
PLoS Pathog; 2020 Jan; 16(1):e1008231. PubMed ID: 31905227
[TBL] [Abstract][Full Text] [Related]
31. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis.
Yi C; Shen Z; Stemmer-Rachamimov A; Dawany N; Troutman S; Showe LC; Liu Q; Shimono A; Sudol M; Holmgren L; Stanger BZ; Kissil JL
Sci Signal; 2013 Sep; 6(291):ra77. PubMed ID: 24003254
[TBL] [Abstract][Full Text] [Related]
32. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
33. Hippo pathway in mammary gland development and breast cancer.
Shi P; Feng J; Chen C
Acta Biochim Biophys Sin (Shanghai); 2015 Jan; 47(1):53-9. PubMed ID: 25467757
[TBL] [Abstract][Full Text] [Related]
34. Angiomotin regulates budding and spread of Ebola virus.
Han Z; Ruthel G; Dash S; Berry CT; Freedman BD; Harty RN; Shtanko O
J Biol Chem; 2020 Jun; 295(25):8596-8601. PubMed ID: 32381509
[TBL] [Abstract][Full Text] [Related]
35. NEDD4L-mediated Merlin ubiquitination facilitates Hippo pathway activation.
Wei Y; Yee PP; Liu Z; Zhang L; Guo H; Zheng H; Anderson B; Gulley M; Li W
EMBO Rep; 2020 Dec; 21(12):e50642. PubMed ID: 33058421
[TBL] [Abstract][Full Text] [Related]
36. The Angiomotins--from discovery to function.
Moleirinho S; Guerrant W; Kissil JL
FEBS Lett; 2014 Aug; 588(16):2693-703. PubMed ID: 24548561
[TBL] [Abstract][Full Text] [Related]
37. Angiomotin Family Members: Oncogenes or Tumor Suppressors?
Lv M; Shen Y; Yang J; Li S; Wang B; Chen Z; Li P; Liu P; Yang J
Int J Biol Sci; 2017; 13(6):772-781. PubMed ID: 28656002
[TBL] [Abstract][Full Text] [Related]
38. Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity.
Mindos T; Dun XP; North K; Doddrell RD; Schulz A; Edwards P; Russell J; Gray B; Roberts SL; Shivane A; Mortimer G; Pirie M; Zhang N; Pan D; Morrison H; Parkinson DB
J Cell Biol; 2017 Feb; 216(2):495-510. PubMed ID: 28137778
[TBL] [Abstract][Full Text] [Related]
39. Cancer stem cells: the promise and the potential.
Ajani JA; Song S; Hochster HS; Steinberg IB
Semin Oncol; 2015 Apr; 42 Suppl 1():S3-17. PubMed ID: 25839664
[TBL] [Abstract][Full Text] [Related]
40. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
Li H; Gumbiner BM
Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
